Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

methenamine mandelate-sodium acid phosphate

methenamine mandelate-sodium acid phosphate
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Uroqid-Acid No.2 TABLET, ORAL 500 mg- 500 mg    
Comments:

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

methenamine mandelate-sodium acid phosphate (Uroqid-Acid No. 2)

  • 500 mg-500 mg tablet oral QID
  • TWO 500 mg-500 mg tablets (Total: 1,000 mg-1,000 mg) QID

methenamine mandelate (Mandelamine)                                                                            

  • 500 mg tablet QID
  • TWO 500 mg tablet (Total: 1,000 mg) QID
Last updated: Jun. 16, 2016






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved